Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021
JAMA Internal Medicine · 01.03.2023 · 183 (3) · 275
DOI: 10.1001/jamainternmed.2022.6299 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.03.2023. Verfasst von Junyi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hos…. Hauptthemen laut MEDLINE: Medicaid, Citric Acid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study assesses Medicaid spending associated with citrate-free vs original adalimumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Wang, J., Lee, C. C., Kesselheim, A. S., & Rome, B. N. (2023). Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021. JAMA Internal Medicine, 183(3), 275. https://doi.org/10.1001/jamainternmed.2022.6299
Vancouver
Wang J, Lee CC, Kesselheim AS, Rome BN. Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021. JAMA Internal Medicine. 2023;183(3):275. doi:10.1001/jamainternmed.2022.6299
BibTeX
@article{Wang2023,
author = {Wang, Junyi and Lee, ChangWon C and Kesselheim, Aaron S and Rome, Benjamin N},
title = {Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021},
journal = {JAMA Internal Medicine},
year = {2023},
volume = {183},
number = {3},
pages = {275},
doi = {10.1001/jamainternmed.2022.6299}
}
EUVIMED